NCT07159828 2026-01-09
A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors
Instil Bio
Phase 1 Active not recruiting
Instil Bio
Chengdu Baiyu Pharmaceutical Co., Ltd.
Centre Hospitalier Universitaire Vaudois
ImmuneSensor Therapeutics Inc.